Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
View/ Open
Date
2022-01-02ICR Author
Author
Vyse, S
Huang, PH
Type
Journal Article
Metadata
Show full item recordAbstract
INTRODUCTION: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations following progression on chemotherapy, marking a watershed moment for a class of mutations which is generally associated with poor outcomes. AREAS COVERED: In this article, we outline the drug profile of amivantamab compared with EGFR kinase inhibitors under evaluation in EGFR exon 20 insertion mutant NSCLC. We also review the efficacy and safety data reported from the CHRYSALIS phase I trial, which forms the basis of the recent approval of amivantamab. EXPERT OPINION: Unlike small molecule EGFR kinase inhibitors, amivantamab has an extracellular mode of action and dual activity against EGFR and MET. It remains to be determined what role MET inhibition plays in toxicity and efficacy and whether dual target inhibition can delay the onset of drug resistance in these cancers. Due to its large molecular size, amivantamab is expected to have poor activity to treat brain metastases. Building on the clinical data so far, future trials that will evaluate combination treatments with brain-penetrant EGFR kinase inhibitors will be critical to move the drug toward a first-line treatment.
Collections
Subject
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Antibodies, Bispecific
Protein Kinase Inhibitors
Mutation
Exons
ErbB Receptors
Research team
Molecular and Systems Oncology
Language
eng
Date accepted
2021-12-07
Citation
Expert review of anticancer therapy, 2022, 22 (1), pp. 3 - 16
Publisher
TAYLOR & FRANCIS LTD